Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 7/20 | 0.35 |
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 0.35 |
| ▸ | SLC6A3 known ✓ | Q01959 | 5/20 | 0.35 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.33 |
| ▸ | HRH1 known ✓ | P35367 | 1/20 | 0.32 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.50 |
| ▸ | NOS3 | P29474 | 2/20 | 0.44 |
| ▸ | NOS1 | P29475 | 2/20 | 0.44 |
| ▸ | NOS2 | P35228 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | AOC1 | P19801 | 3/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 3/20 | 0.34 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL18765302 | 1.00 | UHRF1 (0.50) | UHRF1NOS3NOS1NOS2KDM4E | |
| Hydrochloric Acid SCHEMBL29505702 | 1.00 | UHRF1 (0.50) | UHRF1NOS3NOS1NOS2KDM4E | |
| SCHEMBL317221 | 0.98 | UHRF1 (0.52) | UHRF1NOS3NOS1NOS2KDM4E | |
| SCHEMBL29707486 | 0.98 | UHRF1 (0.52) | UHRF1NOS3NOS1NOS2KDM4E | |
| Formaldehyde SCHEMBL28853991 | 0.92 | UHRF1 (0.47) | UHRF1NOS3NOS1NOS2KDM4E | |
| Hydrochloric Acid SCHEMBL2750563 | 0.83 | UHRF1 (0.45) | UHRF1NOS3NOS1NOS2KDM4E | |
| Hydrochloric Acid SCHEMBL7049175 | 0.81 | NOS3 (0.68) | UHRF1NOS3NOS1NOS2KDM4E | |
| Hydrochloric Acid SCHEMBL17442768 | 0.81 | NOS3 (0.68) | UHRF1NOS3NOS1NOS2KDM4E | |
| SCHEMBL317800 | 0.80 | UHRF1 (0.46) | UHRF1NOS3NOS1NOS2CYP1A2 | |
| SCHEMBL11616480 | 0.80 | UHRF1 (0.46) | UHRF1NOS3NOS1NOS2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| EP-3364967-B1 | FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2026-05-14 | — | — | US | disclosed |
| EP-3365339-B1 | NOVEL FERROPORTIN INHIBITORS | VIFOR INT AG (CH) | 2025-07-16 | — | — | EP | disclosed |
| CN-120077042-A | 3A,4,5, 6-tetrahydro-1H-pyrazolo [3,4-C ] pyridin-7 (7 AH) -one derivatives as factor XIIa inhibitors | 卡尔维斯塔制药有限公司 | 2025-05-30 | — | — | CN | disclosed |
| WO-2024084217-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2024-04-25 | — | — | WO | disclosed |
| US-20220363675-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2022-11-17 | — | — | US | disclosed |
| CN-114668761-A | Novel ferroportin inhibitors | 威佛（国际）股份公司 | 2022-06-28 | — | — | CN | disclosed |
| CN-108290878-B | Novel ferroportin inhibitors | 威佛（国际）股份公司 | 2022-04-26 | — | — | CN | disclosed |
| US-11066399-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-10364239-B2 | Ferroportin inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2019-07-30 | — | — | US | disclosed |
| US-20180319783-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2018-11-08 | — | — | US | disclosed |
| US-20180297991-A1 | Novel Ferroportin Inhibitors | VIFOR (INTERNATIONAL) AG (CH) | 2018-10-18 | — | — | US | disclosed |
| EP-3364967-A2 | FERROPORTIN INHIBITORS | Vifor (International) AG (CH) | 2018-08-29 | — | — | EP | disclosed |
| EP-3365339-A1 | NOVEL FERROPORTIN INHIBITORS | Vifor (International) AG (CH) | 2018-08-29 | — | — | EP | disclosed |
| WO-2017068089-A2 | NOVEL FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2017-04-27 | — | — | WO | disclosed |
| WO-2017068090-A1 | NOVEL FERROPORTIN INHIBITORS | VIFOR (INTERNATIONAL) AG (CH) | 2017-04-27 | — | — | WO | disclosed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | F11, F13B, F7 | SLC6A4 4539/4885SLC6A2 4482/4885SLC6A3 4625/4885 |
| US-11066399-B2 | Ferroportin inhibitors | HAMP, SLC40A1, FTH1 | SLC6A4 3056/4885SLC6A2 1248/4885SLC6A3 2935/4885 |
| US-20180297991-A1 | Novel Ferroportin Inhibitors | SLC40A1, HAMP, TFRC | SLC6A4 2495/4885SLC6A2 1085/4885SLC6A3 1422/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | SLC6A4 2705/4885SLC6A2 3703/4885SLC6A3 1721/4885 |
| US-10364239-B2 | Ferroportin inhibitors | HAMP, SLC40A1, HMOX1 | SLC6A4 3044/4885SLC6A2 1131/4885SLC6A3 3108/4885 |
| US-20180319783-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, FTH1 | SLC6A4 3175/4885SLC6A2 1290/4885SLC6A3 3186/4885 |
| US-20220363675-A1 | Novel Ferroportin Inhibitors | HAMP, SLC40A1, HMOX1 | SLC6A4 3379/4885SLC6A2 1420/4885SLC6A3 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.